JAMES SELLMAN: Open Payments
NPI 1225118805 · RICHMOND, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,519 in 146 payments from 20 companies in 2025. Trend: 2023 $2,998 · 2024 $3,183 · 2025 $3,519
Food & beverage: $3,519
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 25 | $762 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $533 |
| ABBVIE INC. | 21 | $521 |
| Otsuka America Pharmaceutical, Inc. | 23 | $508 |
| E.R. Squibb & Sons, L.L.C. | 11 | $259 |
| Alkermes, Inc. | 11 | $224 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| Collegium Pharmaceutical, Inc. | 6 | $101 |
| Neos Therapeutics, LP | 4 | $70 |
| Lundbeck LLC | 3 | $59 |
Products named: FANAPT, CAPLYTA, VRAYLAR, REXULTI, COBENFY, ARISTADA, INGREZZA, Jornay PM.
Industry payments across VA — which companies pay providers there.
